Hola,
Are you new here?

ProCAncer-I

financed

An AI Platform integrating imaging data and models supporting precision care th...

An AI Platform integrating imaging data and models supporting precision care through prostate cancer s continuum In Europe, prostate cancer (PCa) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices, often leading to overdiagnosis and overtreatment of indolent tumors, suffer from lack of pre... see more

30/09/2024

FOUNDATION FOR RES...

10M€

Project Budget: 10M€

Project leader

IDRYMA TECHNOLOGIAS KAI EREVNAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 23 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2024-09-30

DT-TDS-05-2020: AI for Health Imaging Specific Challenge:Artificial Intelligence (AI) offers substantial opportunities for healthcare, sup...

I+D

Cerrada does 5 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

23 Participantes

FOUNDATION FOR RESEARCH AND...

1.37M€ | Leader

ULBASA

327.34K€ | participant

IPC

150.00K€ | participant

HACETTEPE UNIVERSITESI

400.00K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 52 months Date Start: 2020-05-29
End date: 2024-09-30

Project leader

IDRYMA TECHNOLOGIAS KAI EREVNAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 10M€

participation deadline Sin fecha límite de participación.

Project description In Europe, prostate cancer (PCa) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices, often leading to overdiagnosis and overtreatment of indolent tumors, suffer from lack of precision calling for advanced AI models to go beyond SoA by deciphering non-intuitive, high-level medical image patterns and increase performance in discriminating indolent from aggressive disease, early predicting recurrence and detecting metastases or predicting effectiveness of therapies. To date efforts are fragmented, based on single–institution, size-limited and vendor-specific datasets while available PCa public datasets (e.g. US TCIA) are only few hundred cases making model generalizability impossible. The ProCAncer-I project brings together 20 partners, including PCa centers of reference, world leaders in AI and innovative SMEs, with recognized expertise in their respective domains, with the objective to design, develop and sustain a cloud based, secure European Image Infrastructure with tools and services for data handling. The platform hosts the largest collection of PCa multi-parametric (mp)MRI, anonymized image data worldwide (>17,000 cases), based on data donorship, in line with EU legislation (GDPR). Robust AI models are developed, based on novel ensemble learning methodologies, leading to vendor-specific and -neutral AI models for addressing 8 PCa clinical scenarios. To accelerate clinical translation of PCa AI models, we focus on improving the trust of the solutions with respect to fairness, safety, explainability and reproducibility. Metrics to monitor model performance and a causal explainability functionality are developed to further increase clinical trust and inform on possible failures and errors. A roadmap for AI models certification is defined, interacting with regulatory authorities, thus contributing to a European regulatory roadmap for validating the effectiveness of AI-based models for clinical decision making.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers